HUDSON, Ohio--(BUSINESS WIRE)--Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Lexicomp® Online™, its hospital-wide referential drug information solution, now includes its industry-leading Facts & Comparisons® Off-Label database and VisualDx® drug eruption content. The enhancements are part of an ongoing integration of Wolters Kluwer Clinical Drug Information solutions to deliver to clinicians extensive medication decision support at the point of care.
The Facts & Comparisons Off-Label database provides information on more than 1,200 off-label medication uses, therapy statements, and evidence ratings, enhancing patient safety and providing valuable context. Users can also access nearly 350 in-depth off-label monographs including dosing studies and risk/benefits discussion for more informed decision-making. Availability of off-label indication information helps improve efficiencies by providing a summary statement of uses within core drug content while also enabling more in-depth research with intuitive access to a deeper level of information to support treatment recommendations and clinician education.
Also newly integrated with Lexicomp Online is industry-leading VisualDx drug eruption content to help clinicians identify drug-induced conditions of the skin. Offered by Logical Images, VisualDx is recognized as the premier solution that aids clinicians in the identification of a variety of skin lesions. By entering visual and other cues, such as lesion type, clinicians can quickly and easily confirm skin reactions and link directly to drug eruption content within Lexicomp drug monographs in the Warnings and Precautions fields. This integration also helps clinicians identify appropriate ICD-9 and ICD-10 codes and provides additional related information, such as supportive patient care and therapy options.
“Health systems and clinicians have long valued the strength of Lexicomp Online for delivering powerful and relevant drug information at the point of care, where it is most needed,” said Steven Kerscher, Vice President & General Manager, Clinical Drug Information, Wolters Kluwer Health, Clinical Solutions. “Incorporation of rich, evidence-based content from Facts & Comparisons, VisualDx and other trusted Wolters Kluwer applications enhances this value by supporting pharmacotherapy decisions that contribute to improved patient safety and clinical outcomes.”
About Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries worldwide, clinicians rely on Wolters Kluwer Health’s market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medi-Span®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical and UpToDate®.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2013 annual revenues of €3.6 billion ($4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Follow our official Twitter handle: @WKHealth.